• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Estimation of General Practitioner Visits, Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus and Infl

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2025 Dec 5;12(12):ofaf735.
doi: 10.1093/ofid/ofaf735. eCollection 2025 Dec. Estimation of General Practitioner Visits, Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus and Influenza Virus, and Costs Associated With Hospitalizations, in Older Adults in France From 2010 to 2020

Charles Nuttens[SUP] 1 [/SUP], Vanessa Barbet[SUP] 2 [/SUP], Clélia Bignon-Favary[SUP] 2 [/SUP], Emilie Lambourg[SUP] 2 [/SUP], Stéphane Fiévez[SUP] 1 [/SUP], Emmanuelle Blanc[SUP] 1 [/SUP], Mathias Vacheret[SUP] 1 [/SUP], Hervé Liliu[SUP] 3 [/SUP], Philippe Vanhems[SUP] 4 5 [/SUP], Jean-Sébastien Casalegno[SUP] 6 [/SUP], Laurence Watier[SUP] 7 [/SUP], Paul Loubet[SUP] 8 [/SUP], Caihua Liang[SUP] 9 [/SUP], Elizabeth Begier[SUP] 10 [/SUP], Magali Lemaitre[SUP] 2 11 [/SUP]



Affiliations
Abstract

Background: Respiratory syncytial virus (RSV) and influenza virus are leading causes of respiratory infections, causing substantial numbers of hospitalizations and deaths, particularly among vulnerable groups such as infants and older adults. While the burden of influenza virus infection is well-documented, the burden of RSV infection in the adult population is often underestimated due to diagnostic challenges and infrequent standard-of-care testing. This study aimed to estimate the incidence of general practitioner (GP) visits, hospitalizations, and deaths attributable to RSV and influenza virus infections in French adults aged ≥50 years, with a focus on ≥65 years, using a time-series model-based approach. In addition, costs associated with hospitalizations were calculated.
Methods: Cyclic Poisson regression models and weekly data from French medical administrative databases and electronic medical records over ten epidemic seasons (2010-2020) were used to estimate incidences for RSV and influenza. The results were stratified by age group, diagnosis causes (respiratory and cardiorespiratory) and diagnosis type (primary and secondary). Average costs per hospitalization were calculated and multiplied by the number of hospitalizations estimated.
Results: Among adults aged ≥65 years, we estimated RSV infection was responsible for 647 619 GP visits 24 319 hospitalizations, and 878 deaths per year. Incidence rates for GP visits for RSV were twice as large as for influenza; hospitalization rates were similar and mortality was lower. The mean annual cost of RSV-attributable hospitalizations was 105 million €, similar to influenza.
Conclusions: This study highlighted the burden of RSV disease in the adult population in France is higher than previous reported. We envisage that this model-based approach will be instrumental in evaluating the impact of RSV vaccination campaigns.

Keywords: France; RSV; incidence; influenza; time-series modeling.

 
Back
Top Bottom